Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038649 | 0.91 | MAP2K4 (0.41) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL2038957 | 0.86 | MEN1 (0.42) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2039704 | 0.85 | KMT2A (0.43) | MEN1KMT2ALMNAMAPTEGFR | |
| SCHEMBL2044273 | 0.83 | NOX4 (0.49) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2044884 | 0.81 | GAA (0.40) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2041507 | 0.81 | KMT2A (0.42) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL2037130 | 0.81 | ANO1 (0.46) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2042920 | 0.79 | GAA (0.40) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2043091 | 0.79 | MAPT (0.47) | MEN1KMT2AGAALMNAMAPT | |
| SCHEMBL2043902 | 0.77 | NPSR1 (0.45) | MEN1KMT2AGAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202346-B2 | Phenol derivatives and the pharmaceutical or cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-02-12 | — | — | US | claimed |
| EP-2516400-B1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RES & DEV (FR) | 2017-03-22 | — | — | EP | claimed |
| US-20130178633-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | claimed |
| US-10202346-B2 | Phenol derivatives and the pharmaceutical or cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-2516400-B1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RES & DEV (FR) | 2017-03-22 | — | — | EP | disclosed |
| US-20160068488-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | COLLETTE PATRICE LUCIEN MAURICE (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20130178633-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2516400-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | Galderma Research & Development (FR) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077046-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068488-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | TYR, MITF, CUTA | MEN1 3059/4885KMT2A 2277/4885GAA 132/4885 |
| US-20130178633-A1 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF | TYR, MITF, CUTA | MEN1 3059/4885KMT2A 2277/4885GAA 132/4885 |
| US-10202346-B2 | Phenol derivatives and the pharmaceutical or cosmetic use thereof | TYR, MITF, CUTA | MEN1 3059/4885KMT2A 2277/4885GAA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.